Skip to Content


Advancing blood safety with
high sensitivity immunoassays



Advancing blood safety with high sensitivity immunoassays

One of the world’s leading providers of plasma screening and blood plasma-based products has approached Volpi to develop and manufacture a multi-channel optical reader for highly sensitive multiplex immunoassays with the goal of producing a lower-cost, higher-performing, more available blood testing alternative to traditional PCR – all enabled by Single Molecule Counting technology.

The technology will be expanded to at least three fluorescence channels with an ultra-low limit of detection in the femtomolar range in multiplex assays for the early detection of infectious diseases. For high throughput, the available read time per sample is fast, around a few seconds.

To learn how Volpi’s intelligent optical solution is helping the company strengthen its leading position in the serology screening of plasma and blood complementing its market-leading position in the screening of plasma using NAT, download our Case Study here.

About Volpi


We improve patient’s lives through light-created insights. Volpi helps healthcare professionals make more informed treatment decisions by delivering innovative optoelectronic solutions that enhance the performance of the diagnostic instruments used to research and diagnose disease. With offices in the US and Switzerland, and clients around the globe, Volpi works with the world’s best-known and most respected Life Sciences and Diagnostics instrument manufacturers.